Cyclin D1 Immunohistochemical Expression in Sudanese Patients Affected with Prostatic Carcinoma in Khartoum State


Prostatic carcinoma is a common public health problem in aging people. Cyclin D1 proto-oncogene is an important regulator of G1 to S phase progression in many different cell types. It is believed to play an important role in both tumorigenesis and grading of many cancers including prostatic carcinoma; high levels of these proteins have been reported in certain human malignancies and have been implicated in aberrant cell division and dysregulated tumor growth. The aims of this study was to examine the immunohistochemical expression of Cyclin D1 in prostatic carcinoma and to demonstrate the association or relation between Cyclin D1 expressions and to determine the aggressiveness of the malignant tumors by Gleason Score. In this study, 50 samples, 25 cases of prostatic cancer and 25 cases of benign prostatic tissues, were studied for Cyclin D1 expression using an immunohistochemical technique which was performed on routinely processed, formalin-fixed, and paraffinembedded tissues; the tissues were then sectioned into thickness of (3–5 µm) with rotary microtome instrument, and immunohistochemical expression of Cyclin D1 was evaluated in all cases. All of the primary human prostatic cancer samples revealed in different ranges of intensity from weak (+1), moderate (+2) to strongly positive nuclear staining (+3) for Cyclin D1. In this study, we revealed no nuclear staining in
the benign prostatic hyperplasia (PBH) disease (+0) in 21 cases (84%), and 4 cases (16%) were ranged in different color intensity; 3 (12%) were weak (1+) and 1 (4%) was moderate (2+), while prostatic cancer cases were also evaluated in different color intensity; 13 cases (52%) were (+3), 7 (28%) were (+2), 3 were (12%) were (+1), and only two (8%) were negative. There was no significance correlation between Gleason’s score and the intensity of Cyclin D1 expression. Conclusively, it can be said that Cyclin D1 may be helpful in the differentiation between BPH and prostate cancer, the correlation between the intensity of Cyclin D1 expression and prostatic diseases was statistically highly significant (p-value = 0.00). The authors recommend to use Cyclin D1 as a tumor marker to prostatic carcinoma.

[1] Alqahtani, F., Atta, I. S., and Mady, E. A. (2015). p63 and Cyclin D1 expression in benign prostatic hyperplasia versus prostatic adenocarcinoma :A clinicopathologic radiologic and immunohistochemical study. International Journal of Healthcare Sciences, pp 305–320.

[2] Chen, C. D., Welsbie, D. S., Tran, C., et al. (2004). Molecular determinants of resistance to antiandrogen therapy. Nature Medicine, vol. 10, no. 1, p. 33.

[3] Comstock, C. E. S., Revelo, M. P., Buncher, C. R., et al. (2007). Impact of differential cyclin D1 expression and localisation in prostate cancer. British Journal of Cancer, vol. 96, no. 6, p. 970.

[4] De Marzo, A. M., Platz, E. A., Sutcliffe, S., et al. (2007). Inflammation in prostate carcinogenesis. Nature Reviews Cancer, vol. 7, no. 4, pp. 256–269.

[5] Drobnjak, M., Osman, I., Scher, H. I., et al. (2000). Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clinical Cancer Research, vol. 6, no. 5, pp. 1891–1895.

[6] Ferlay, J., Shin, H. R., Bray, F., et al. (2010). GLOBOCAN (2008). Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10. International Agency for Research on Cancer. Lyon, France.

[7] Fleischmann, A., Rocha, C., Saxer-Sekulic, N., et al. (2011). High CD10 expression in lymph node metastases from surgically treated prostate cancer independently predicts early death. VirchowsArchiv, vol. 458, no. 6, pp. 741–748.

[8] Gupta, V., Singh, S., Sen, R., et al. (2014). Role of cyclin D1 immunoreactivity and AgNOR staining in the evaluation of benign and malignant lesions of the prostate. Prostate International, vol. 2, no. 2, pp. 90–96.

[9] Han, E. K. H., Lim, J. T., Arber, N., et al. (1998). Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors. The Prostate, vol. 35, no. 2, pp. 95–101.

[10] He, Y., Franco, O. E., Jiang, M., et al. (2007).Tissue-specific consequences of cyclin D1 overexpression in prostate cancer progression. Cancer Research, vol. 67, no. 17, pp. 8188–8197.

[11] Hosni, H. N. and El-Rahman, M. A. (2010). Immunohistochemical Expression of Cyclin D1 in Egyptian patients with prostatic carcinoma. The Medical Journal of Cairo University, vol. 78, no. 2.

[12] Kallakury, B. V., Sheehan, C. E., Ambros, R. A., et al. (1997). The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma. Cancer, vol. 80, no. 4, pp. 753–763.

[13] Murphy, G. P., Busch, C., Abrahamsson, P. A., et al. (1993–1994). Histopathology of localized prostate cancer. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12–13. Scandinavian Journal of Urology and Nephrology, vol. 162, pp. 7–42; discussion 115–127.

[14] Nagla, M. A. G, EL Sadig, A. A., and Nada, S. S. (2016). Immune histochemical prostatic evaluation of cyclin D1 in adenocarcinoma and benign prostatic hyperplasia in small neddle biopsy of Sudanese patient. European Academic Research. IF:3.4546.

[15] Ozbek, E., Mizrak, B.Ü.L.E.N.T., Ozbek, M., et al. (2000). Cyclin-D1 protooncogene expression in prostate cancer. Turkish Journal of Cancer, vol. 30, no. 30, pp. 15–21.

[16] Raju, B., Mehrotra, R., Øijordsbakken, G., et al. (2005). Expression of p53, cyclin D1 and Ki-67 in pre-malignant and malignant oral lesions: Association with clinicopathological parameters. Anticancer Research, vol. 25, no. 6C, pp. 4699–4706.

[17] Saeed, I. E., Weng, H. Y., Mohamed, K. H., et al. (2014). Cancer incidence in Khartoum, Sudan: first results from the Cancer Registry, 2009n2010. Cancer Medicine, vol. 3, no. 4, pp. .1084–1075

[18] Samia, M., Gabal, M. D., Samar, A., et al. (2017). Immunohistochemical expression of cyclin D1 and Ki 67 in premalignant and malignant prostatic lesions. International Journal of Advanced Research, vol. 5, no. 8, pp. 1553–1561.

[19] Shen, M. M. and Abate-Shen, C. (2010). Molecular genetics of prostate cancer: New prospects for old challenges. Genes & Development, vol. 24, pp. 1967–2000.

[20] Shiraishi, T., Watanabe, M., Muneyuki, T., et al. (1998). A clinicopathological study of p53, p21 (WAF1/CIP1) and cyclin D1 expression in human prostate cancers. Urologiainternationalis, vol. 61, no. 2, pp. 90–94.

[21] Ueda, N., Yamashita, M., Kuroda, I., et al. (2001). Immunohistological evaluation of the expression of P27 and cyclin D1 in prostatic specimens. Nishinihon Journal of Urology, vol. 63, no. 4, pp. 246–249.